Share

April 03, 2018; 90 (14) Editorial

Central vein sign in multiple sclerosis

Ready for front and center?

Aaron E. Miller, Peter A. Calabresi
First published March 7, 2018, DOI: https://doi.org/10.1212/WNL.0000000000005241
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
295

Share

Article Information

vol. 90 no. 14 631-632
DOI: 
https://doi.org/10.1212/WNL.0000000000005241
PubMed: 
29514945
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • First Published March 7, 2018.

Article Versions

Copyright & Usage: 
© 2018 American Academy of Neurology

Author Disclosures

    1. Aaron E. Miller, MD and
    2. Peter A. Calabresi, MD
  1. Aaron E. Miller, MD and
    2. Scientific Advisory Boards:

    1. Genzyme/Sanofi-aventis, Biogen Idec, GlaxoSmithKline, EMD Serono, Teva Neuroscience; Novartis, Acorda, Mallinckrodt (Questcor); Alkermes; Roche/Genentech; Caremark (Accordant Health Services); Celgene; Adamas Pharmaceuticals; Mapi-Pharma;

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Travel to advisory board meetings for Genzyme/sanofi aventis, Biogen Idec, EMD Serono, Novartis, Acorda; Roche/Genentech; Celgene, Adamas; Speakers honoraria from Roche/Genentech and Biogen (for non-branded programs only)

    Editorial Boards:

    1. Continuum Audio (AAN) received fees as editor 2012-present Associate Editor, Multiple Sclerosis and Related Disorders

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Genzyme/Sanofi-aventis, Biogen Idec, GlaxoSmithKline, EMD Serono, Teva Neuroscience; Novartis, Acorda, Mallinckrodt (Questcor); Alkermes; Roche/Genentech; Caremark (Accordant Health Services); Adamas Pharmaceuticals; Mapi-Pharma

    Speakers' Bureaus:

    1. Biogen Idec (only for an unbranded disease awareness program) Genentech/Roche (only for an unbranded programH)

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Acorda, Novartis, Roche, Mallinckrodt (Questcor), Genzyme/Sanofi-aventis Biogen Idec Genentech, Alkermes; MedDay

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. I have occasionally reviewed medico-legal cases as a defense expert; the cases are not in the public domain and remain confidential. I have served as an expert witness for a lawyer representing Chubb Insurance Company in which I assessed the MS status of the plaintiff who brought suit against Chubb.

  2. Peter A. Calabresi, MD
    3. Scientific Advisory Boards:

    1. 1. DiSARM Therapeutics 2. Biogen

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. 1. NMSS (travel only) 2. Myelin Repair Foundation (travel and honorarium) 3. MSAA (travel and honorarium)

    Editorial Boards:

    1. Neurology Editorial Board 2007 to 2017 Journal of Clinical Investigation Associate Editor-present

    Patents:

    1. NONE

    Publishing Royalties:

    1. Optical Coherence Tomography in Neurological Diseases (book) Royalties for being co-editor received from Cambridge Press.

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. 1. DiSARM Therapeuuutics 2. Biogen

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical procedures or imaging studies:

    1. We utilize OCT in the clinic and bill for patients not enrolled in research studies. I have been a co-author on papers outlining guidelines for use of OCT.

    Research Support, Commercial Entities:

    1. 1 Biogen-IDEC 2. Novartis OCTiMS study (no drug involved) 3. MedImmune 4. Teva 5. Annexon 6. Genzyme

    Research Support, Government Entities:

    1. NIH, NINDS NS R-37 041435 PI 2013-2020 PI NIH, NINDS R-01 NS082347-01 2013-2018 PI

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NMSS Collaborative Center Grant 2012-2017 Nancy Davis Race to Erase MS Foundation

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Corinne Goldsmith Dickinson Center for Multiple Sclerosis (A.E.M.), Icahn School of Medicine at Mount Sinai, New York, NY; and MS Center and Division of Neuroimmunology and Neuroinfectious Diseases (P.A.C.), Johns Hopkins University School of Medicine, Baltimore, MD.
  1. Correspondence
    Dr. Miller Aaron.miller{at}mssm.edu
View Full Text

Article usage

Article usage: March 2018 to April 2022

AbstractFullPdfSource
Mar 2018336359Highwire
Apr 201839314173Highwire
May 2018145714Highwire
Jun 2018861311Highwire
Jul 20189788Highwire
Aug 20187366Highwire
Sep 20187957Highwire
Oct 2018113313Highwire
Nov 201811177Highwire
Dec 2018126325Highwire
Jan 201985814Highwire
Feb 20191241210Highwire
Mar 2019111106Highwire
Apr 20196086Highwire
May 20197386Highwire
Jun 20195111Highwire
Jul 20192651Highwire
Aug 20194921Highwire
Sep 20191511Highwire
Oct 20193350Highwire
Nov 20193432Highwire
Dec 20191511Highwire
Jan 20202432Highwire
Feb 20202061Highwire
Mar 20203800Highwire
Apr 20201633Highwire
May 20201011Highwire
Jun 20202320Highwire
Jul 20201521Highwire
Aug 20201121Highwire
Sep 20201410Highwire
Oct 20203011Highwire
Nov 20201221Highwire
Dec 20201010Highwire
Jan 20213130Highwire
Feb 20211020Highwire
Mar 20211610Highwire
Apr 20211231Highwire
May 20211701Highwire
Jun 20212011Highwire
Jul 20211200Highwire
Aug 20211321Highwire
Sep 20212710Highwire
Oct 20211101Highwire
Nov 2021700Highwire
Dec 20211412Highwire
Jan 20221424Highwire
Feb 20221611Highwire
Mar 2022900Highwire
Apr 20221200Highwire

Cited By...

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

Alert Me